Compare Organon & Co. (OGN) vs Novartis AG (NVS) Stock

Organon & Co. (OGN) offers the better valuation at 10.1x trailing P/E (2.1x forward), making it the more compelling value choice. Analysts rate Organon & Co. (OGN) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Organon & Co. (OGN) is the cheapest at 10.1x versus Novartis AG at 23.5x. On forward P/E, Organon & Co. is actually cheaper at 2.1x.

Over the past 5 years, Novartis AG (NVS) delivered a total return of +119.5%, compared to -65.2% for Organon & Co. (OGN). A $10,000 investment in NVS five years ago would be worth approximately $22K today (assuming dividends reinvested). Over 10 years, the gap is even starker: NVS returned +221.6% versus OGN's -65.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Novartis AG (NVS) is the lower-risk stock at 0.24β versus Organon & Co.'s 0.92β — meaning OGN is approximately 281% more volatile than NVS relative to the S&P 500.

Novartis AG (NVS) is the more profitable company, earning 25.6% net margin versus 3.0% for Organon & Co. — meaning it keeps 25.6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVS leads at 31.2% versus 20.7% for OGN. At the gross margin level — before operating expenses — NVS leads at 75.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Organon & Co. (OGN) trades at 2.1x forward P/E versus 19.0x for Novartis AG — 16.9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OGN: -10.8% to $6.50.

In this comparison, NVS (2.4% yield) pays a dividend. OGN does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Novartis AG (NVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.24), 2.4% yield, +221.6% 10Y return). Both have compounded well over 10 years (NVS: +221.6%, OGN: -65.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: OGN is a small-cap deep-value stock; NVS is a large-cap quality compounder stock. NVS pays a dividend while OGN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.